MaxCyte MXCT Business Segments — Allocated Share Based Compensation Expense

Similar metrics at other companies

GRDNCorporate — Allocated Share Based Compensation Expense

$1.86M-53.1%

AMT

AMTXCalifornia Ethanol — Allocated Share Based Compensation Expense

$0—

LPTHAllocated Share Based Compensation Expense Total

$314.07K—

NKTRAll Other Segments — Allocated Share Based Compensation Expense

$3.36M-13.9%

LNSRProduct — Allocated Share Based Compensation Expense

$55K+48.6%

COHUSemiconductor Test Inspection — Allocated Share Based Compensation Expense

$6.28M+0.7%

Questions, answered.

What is MaxCyte's business segments — allocated share based compensation expense?

MaxCyte (MXCT) reported business segments — allocated share based compensation expense of $1.14M in Q1 2026.

How has MaxCyte's business segments — allocated share based compensation expense changed year-over-year?

MaxCyte's business segments — allocated share based compensation expense decreased by 62.5% year-over-year, from $3.04M to $1.14M.

What is the long-term trend for MaxCyte's business segments — allocated share based compensation expense?

Over 2 years (2023 to 2025), MaxCyte's business segments — allocated share based compensation expense has grown at a -18.8% compound annual growth rate (CAGR), from $13.98M to $9.21M.

What does business segments — allocated share based compensation expense mean?

The portion of total share-based compensation expenses attributed to the cell engineering segment, reflecting the cost of equity-based incentives for employees. This is a key metric for understanding the true economic cost of human capital and alignment with shareholder interests.